Cargando…
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling
Therapeutic resistance to immune checkpoint blockers (ICBs) in melanoma patients is a pressing issue, of which tumor loss of IFN-γ signaling genes is a major underlying mechanism. However, strategies of overcoming this resistance mechanism have been largely elusive. Moreover, given the indispensable...
Autores principales: | Shen, Hongxing, Huang, Fengyuan, Zhang, Xiangmin, Ojo, Oluwagbemiga A., Li, Yuebin, Trummell, Hoa Quang, Anderson, Joshua C., Fiveash, John, Bredel, Markus, Yang, Eddy S., Willey, Christopher D., Chong, Zechen, Bonner, James A., Shi, Lewis Zhichang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411168/ https://www.ncbi.nlm.nih.gov/pubmed/36008408 http://dx.doi.org/10.1038/s41467-022-32754-7 |
Ejemplares similares
-
Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
por: Bonner, James A., et al.
Publicado: (2015) -
Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
por: Shi, Lewis Zhichang, et al.
Publicado: (2021) -
HiJAKing Immunotherapy-Resistant Melanoma for a Cure
por: Shi, Lewis Zhichang, et al.
Publicado: (2023) -
Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer
por: Nair, Sindhu, et al.
Publicado: (2020) -
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)